Bryan Johnson has become an unexpected advocate for GLP-1s. During his appearance on the Full Send Podcast, Johnson shared detailed insights about why GLP-1s have earned a place in his carefully monitored health regimen.
“The GLP-1s are the first legit longevity (). If you look at the overall effect on society, it has probably had a bigger consequence on society than any dr*g of this class.”
Johnson stated.
When the hosts brought up the common criticism surrounding GLP-1s like Ozempic, Johnson acknowledged the controversy while defending the therapeutic value.
“There’s, like, two different things. I mean, like, so there’s, like, two different things it worked, you’re just saying how they pitch it to their friends.”
He added: “I don’t know what the shame is.”
Johnson agreed with the hosts’ perspective on transparency.
“I mean, it’s an amazing (). Like, what else out there? There’s just, like, nothing that rivals its efficacy. Yes, there’s side effects; you have to be mindful about that, and it’s not a free lunch, but man, it’s amazing.”
Johnson suggested everyone would benefit from microdosing GLP-1s.
Perhaps the most striking aspect of Johnson’s GLP-1 advocacy is that he uses them despite being in exceptional physical condition.
“I’m as healthy as a person can be, and I still benefit from GLP-1s.”
He revealed. When asked if the benefit stems from appetite suppression, Johnson clarified:
“No, because my dose is way too low for that.”
Johnson explained that he microdoses GLP-1s to access other therapeutic benefits.
“There’s other metabolic effects that have good neural protective effects, like it has a lot of, and then we’re still discovering. But yeah, there’s still a fact about healthy effects.”
The hosts pressed Johnson on what specific effects he experiences.
“For me, what—like, what are those effects? Blood glucose? Like, if you look at my blood glucose, I’m in the 99th percentile for 18-year-olds. So, when you compare my glucose management to an 18-year-old, I’m better than 99 out of 100 18-year-olds.”
This statement highlights Johnson’s core argument: even someone with nearly perfect metabolic markers can benefit from GLP-1 therapy. His glucose management already surpasses 99 percent of teenagers, yet the GLP-1 still provides measurable advantages.
Early clinical research suggests GLP-1 receptor agonists, including semaglutide and tirzepatide, may cut migraine frequency by nearly half in people with overweight or obesity. In a 12-week trial, participants experienced an average of 4.2 fewer migraine days per month, alongside modest weight loss, indicating potential neurological benefits beyond blood sugar and weight management. While the study was small and uncontrolled, the findings highlight a possible new avenue for migraine prevention, though larger trials are needed to confirm effectiveness, dosing, and applicability to people without weight concerns.
The entrepreneur’s comments reflect his broader philosophy of using rigorous testing and measurement to optimize health outcomes.
His team tracks numerous biomarkers continuously, allowing them to assess the true impact of interventions like GLP-1 therapy beyond anecdotal reports.
Johnson’s position on GLP-1s challenges the binary thinking that often surrounds these innovations. Rather than viewing them as either miracle cures or shortcuts for people unwilling to exercise discipline, he presents them as legitimate therapeutic tools with applications beyond weight management.
His personal use despite optimal health metrics suggests GLP-1s may have preventive and longevity benefits that extend well beyond their approved indications.
